Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.
Human leukotriene A4 hydrolase (hLTA4H) is a bi-functional enzyme catalyzes the hydrolase and aminopeptidase functions upon the fatty acid and peptide substrates, respectively, utilizing the same but overlapping binding site. Particularly the hydrolase function of this enzyme catalyzes the rate-limi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3320645?pdf=render |
| _version_ | 1818460597402992640 |
|---|---|
| author | Sundarapandian Thangapandian Shalini John Mahreen Arooj Keun Woo Lee |
| author_facet | Sundarapandian Thangapandian Shalini John Mahreen Arooj Keun Woo Lee |
| author_sort | Sundarapandian Thangapandian |
| collection | DOAJ |
| description | Human leukotriene A4 hydrolase (hLTA4H) is a bi-functional enzyme catalyzes the hydrolase and aminopeptidase functions upon the fatty acid and peptide substrates, respectively, utilizing the same but overlapping binding site. Particularly the hydrolase function of this enzyme catalyzes the rate-limiting step of the leukotriene (LT) cascade that converts the LTA4 to LTB4. This product is a potent pro-inflammatory activator of inflammatory responses and thus blocking this conversion provides a valuable means to design anti-inflammatory agents. Four structurally very similar chemical compounds with highly different inhibitory profile towards the hydrolase function of hLTA4H were selected from the literature. Molecular dynamics (MD) simulations of the complexes of hLTA4H with these inhibitors were performed and the results have provided valuable information explaining the reasons for the differences in their biological activities. Binding mode analysis revealed that the additional thiophene moiety of most active inhibitor helps the pyrrolidine moiety to interact the most important R563 and K565 residues. The hLTA4H complexes with the most active compound and substrate were utilized in the development of hybrid pharmacophore models. These developed pharmacophore models were used in screening chemical databases in order to identify lead candidates to design potent hLTA4H inhibitors. Final evaluation based on molecular docking and electronic parameters has identified three compounds of diverse chemical scaffolds as potential leads to be used in novel and potent hLTA4H inhibitor design. |
| first_indexed | 2024-12-14T23:32:47Z |
| format | Article |
| id | doaj.art-ecda175dbece4d47bad0f758652f6742 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T23:32:47Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ecda175dbece4d47bad0f758652f67422022-12-21T22:43:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3459310.1371/journal.pone.0034593Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.Sundarapandian ThangapandianShalini JohnMahreen AroojKeun Woo LeeHuman leukotriene A4 hydrolase (hLTA4H) is a bi-functional enzyme catalyzes the hydrolase and aminopeptidase functions upon the fatty acid and peptide substrates, respectively, utilizing the same but overlapping binding site. Particularly the hydrolase function of this enzyme catalyzes the rate-limiting step of the leukotriene (LT) cascade that converts the LTA4 to LTB4. This product is a potent pro-inflammatory activator of inflammatory responses and thus blocking this conversion provides a valuable means to design anti-inflammatory agents. Four structurally very similar chemical compounds with highly different inhibitory profile towards the hydrolase function of hLTA4H were selected from the literature. Molecular dynamics (MD) simulations of the complexes of hLTA4H with these inhibitors were performed and the results have provided valuable information explaining the reasons for the differences in their biological activities. Binding mode analysis revealed that the additional thiophene moiety of most active inhibitor helps the pyrrolidine moiety to interact the most important R563 and K565 residues. The hLTA4H complexes with the most active compound and substrate were utilized in the development of hybrid pharmacophore models. These developed pharmacophore models were used in screening chemical databases in order to identify lead candidates to design potent hLTA4H inhibitors. Final evaluation based on molecular docking and electronic parameters has identified three compounds of diverse chemical scaffolds as potential leads to be used in novel and potent hLTA4H inhibitor design.http://europepmc.org/articles/PMC3320645?pdf=render |
| spellingShingle | Sundarapandian Thangapandian Shalini John Mahreen Arooj Keun Woo Lee Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. PLoS ONE |
| title | Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. |
| title_full | Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. |
| title_fullStr | Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. |
| title_full_unstemmed | Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. |
| title_short | Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. |
| title_sort | molecular dynamics simulation study and hybrid pharmacophore model development in human lta4h inhibitor design |
| url | http://europepmc.org/articles/PMC3320645?pdf=render |
| work_keys_str_mv | AT sundarapandianthangapandian moleculardynamicssimulationstudyandhybridpharmacophoremodeldevelopmentinhumanlta4hinhibitordesign AT shalinijohn moleculardynamicssimulationstudyandhybridpharmacophoremodeldevelopmentinhumanlta4hinhibitordesign AT mahreenarooj moleculardynamicssimulationstudyandhybridpharmacophoremodeldevelopmentinhumanlta4hinhibitordesign AT keunwoolee moleculardynamicssimulationstudyandhybridpharmacophoremodeldevelopmentinhumanlta4hinhibitordesign |